NCT00928304View on ClinicalTrials.gov

Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid.

PHASE2CompletedINTERVENTIONAL
Enrollment

109

Participants

Timeline

Start Date

June 30, 2009

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Down SyndromeAmyloid Beta-protein
Interventions
DRUG

Florbetaben (BAY94-9172)

300 megabecquerels (MBq) as single IV injection of 2 to 10 mL

Trial Locations (2)

85351

Sun City

06510

New Haven

Sponsors
All Listed Sponsors
lead

Life Molecular Imaging SA

INDUSTRY

NCT00928304 - Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. | Biotech Hunter | Biotech Hunter